Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Mr. David Tyronne Howton Jr., J.D.

Chief Operating Officer, General Counsel & Secretary

Mr. Paul  Herzich

Chief Technology Officer

Dr. Jennifer  Marlowe Ph.D.

Chief Scientific Officer

Dr. Jessie  Hanrahan Ph.D.

Chief Regulatory Officer

Mr. Kevin  Tan C.F.A.

Chief Financial Officer & Treasurer

Ms. Annie  Ganot

Co-Founder & Head of Patient Advocacy

Ms. Allison  Bogosian J.D.

Senior Vice President of Human Resources

Mr. Ian F. Smith A.C.A., C.P.A.

Executive Chair

Mr. Alexander G. Cumbo

President, Chief Executive Officer & Director

Mr. Ilan  Ganot

Co-founder, Strategic Advisor to the Chief Executive Officer & Director

Биотехнологии

Solid Biosciences Inc.

Solid Biosciences Inc. Структура управления

Информация о руководстве